|Brand name(s), other common name(s)||Sprycel®|
|Drug type||Tyrosine kinase inhibitor|
|How the drug is given||By mouth|
Dasatinib is FDA approved to treat all phases of chronic myeloid leukemia or a type of acute lymphoblastic leukemia called Philadelphia chromosome positive or Ph+ ALL in adults who are no longer benefiting from treatment with the current available therapies for these diseases, including Gleevec® (imatinib mesylate), or who experience severe side effects from Gleevec®.
Special considerations: Tell your doctor if you have any other medical conditions, especially if you have a liver or heart problem or are lactose intolerant.
Side effects needing medical attention:Fever; bleeding or easy bruising; swelling; weight gain; increasing shortness of breath.
Dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension [PAH]). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs).